Lab Analysis Finds Commercial 7-OH Kratom Products Widely Mislabeled, Semisynthetic, and Generating Toxic Gastric Byproduct

Why it matters

Most commercial 7-OH kratom products contain inaccurate doses, are made through semisynthetic manufacturing rather than natural extraction, and break down into a potentially toxic compound in stomach acid — findings with urgent implications for consumer safety and regulatory oversight.

The big picture

7-Hydroxymitragynine (7-OH) is a potent mu-opioid agonist present only in trace amounts in traditional kratom leaves. The rapid rise of concentrated, semi-synthetic 7-OH products has far outpaced regulatory oversight, with the FDA recommending Schedule I classification but DEA scheduling action still pending as of early 2026.

Key findings

• Substantial inconsistencies were found between labeled and actual 7-OH concentrations in commercial products
• Over 98% of 7-OH-labeled products showed evidence of semisynthetic origin — they are not natural kratom extracts
• Labeled doses ranged widely from 0.001 to 33.6 mg per serving, demonstrating extreme variability
• 7-OH degrades into 3-dehydromitragynine — a potentially toxic byproduct — under simulated gastric (stomach acid) conditions
• Products also contained overoxidized byproducts that reveal the synthetic manufacturing process used

What they say

"These findings underscore significant safety concerns over oral 7-OH products and necessitate validated analytical monitoring to guide regulatory oversight and consumer protection," the researchers from the University of Mississippi National Center for Natural Products Research concluded.

Bottom line

Nearly all commercial 7-OH products are mislabeled, made via synthetic chemistry rather than natural kratom, and generate a potentially toxic compound in the stomach — evidence that demands immediate, validated analytical standards for this rapidly growing product category.